Literature DB >> 8262587

Oral iron chelation: a review with special emphasis on Indian work on deferiprone (L1).

M B Agarwal1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8262587     DOI： 10.1007/bf02751427

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   1.967


× No keyword cloud information.
  22 in total

1.  Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial.

Authors:  M B Agarwal; S S Gupte; C Viswanathan; D Vasandani; J Ramanathan; N Desai; R R Puniyani; A T Chhablani
Journal:  Br J Haematol       Date:  1992-10       Impact factor: 6.998

2.  Rarity of systemic lupus erythematosus after oral iron chelator L1.

Authors:  N F Olivieri; G Koren; M H Freedman; C Roifman
Journal:  Lancet       Date:  1991-04-13       Impact factor: 79.321

3.  Fatal systemic lupus erythematosus in patient taking oral iron chelator L1.

Authors:  J Mehta; S Singhal; R Revankar; A Walvalkar; A Chablani; B C Mehta
Journal:  Lancet       Date:  1991-02-02       Impact factor: 79.321

Review 4.  The development of hydroxypyridin-4-ones as orally active iron chelators.

Authors:  R C Hider; S Singh; J B Porter; E R Huehns
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

5.  Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients.

Authors:  N F Olivieri; G Koren; P St Louis; M H Freedman; R A McClelland; D M Templeton
Journal:  Semin Hematol       Date:  1990-04       Impact factor: 3.851

6.  The study of iron mobilisation from transferrin using alpha-ketohydroxy heteroaromatic chelators.

Authors:  G J Kontoghiorghes
Journal:  Biochim Biophys Acta       Date:  1986-01-30

7.  New orally active iron chelators.

Authors:  G J Kontoghiorghes
Journal:  Lancet       Date:  1985-04-06       Impact factor: 79.321

8.  The development of new iron-chelating drugs. II.

Authors:  R W Grady; J H Graziano; G P White; A Jacobs; A Cerami
Journal:  J Pharmacol Exp Ther       Date:  1978-06       Impact factor: 4.030

9.  Efficacy and safety of 1-2, dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassaemia major with iron overload.

Authors:  M B Agarwal; S S Gupte; D Vasandani; C Viswanathan; R R Puniyani; J Ramanathan; D E Massil; S Shah; G C Rajyadhyaksha; A A Bhave
Journal:  J Assoc Physicians India       Date:  1991-09

10.  Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.

Authors:  G J Kontoghiorghes; M A Aldouri; A V Hoffbrand; J Barr; B Wonke; T Kourouclaris; L Sheppard
Journal:  Br Med J (Clin Res Ed)       Date:  1987-12-12
View more
  3 in total

1.  Deferiprone-induced arthropathy in thalassemia: MRI findings in a case.

Authors:  Gyan Chand; Veena Chowdhury; A Manchanda; Sapna Singh
Journal:  Indian J Radiol Imaging       Date:  2009 Apr-Jun

Review 2.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 3.  Past, present & future scenario of thalassaemic care & control in India.

Authors:  Ishwar C Verma; Renu Saxena; Sudha Kohli
Journal:  Indian J Med Res       Date:  2011-10       Impact factor: 2.375
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.